Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB

BIOGEN INC (BIIB)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Biogen Idec Inc. : Biogen 4th-Quarter Profit Falls 2.7% on Higher Costs; Revenue Up

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/28/2013 | 01:13pm CET
   By Tess Stynes and Melodie Warner 
 

Biogen Idec Inc.'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's efforts to bulk up its product pipeline masked its revenue growth.

The company also forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters expect $7.27 a share on a 9% rise in revenue to $5.98 billion.

Biogen on Thursday said a new version of its blockbuster multiple-sclerosis drug Avonex was successful in a late-stage trial, strengthening the company's stable of drugs for the degenerative nerve disease. However, the overall market for such injectable drugs is expected to decline sharply amid a growing market for oral-pill-based drugs. Biogen's own BG-12 pill could be approved and launched in the U.S. as soon as March.

Biogen has been beefing up its sales force and readying its manufacturing supply chain as some drugs in its late-stage product pipeline have been drawing closer to entering the market.

Research and development costs rose 1.8% in the latest period while selling, general and administrative costs jumped 32%.

Biogen reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding items such as stock-option expense, amortization and restructuring charges, per-share earnings fell to $1.40 from $1.51. Revenue increased 6.9% to $1.42 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.46 a share on revenue of $1.39 billion.

In the latest quarter, sales of Avonex rose 7.1% to $753.2 million.

Shares closed Friday at $146.20 and were inactive premarket. The stock is up 23% over the past year.

Write to Tess Stynes at tess.stynes@dowjones.com and Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN INC
12/05 BIOGEN INC : Lundin Law PC Announces Securities Class Action Lawsuit against Bio..
12/05 BIOGEN INC : Shareholder Alert - - Bronstein, Gewirtz & Grossman, LLC Reminds In..
12/03 BIOGEN : Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Lif..
12/01 BIOGEN INC : Khang & Khang LLP Announces Securities Class Action Lawsuit against..
12/01 BIOGEN INC : Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actio..
11/30 BIOGEN INC : Lundin Law PC Announces Securities Class Action Lawsuit against Bio..
11/30 BIIB The Law Offices of Vincent Wong Reminds Shareholders of a Class Action I..
11/28 BIOGEN INC : Khang & Khang LLP Announces Securities Class Action Lawsuit against..
11/28 BIOGEN INC : SHAREHOLDER ALERT Bronstein, Gewirtz & Grossman, LLC Reminds Invest..
11/25 BIOGEN INC : Lundin Law PC Announces Securities Class Action Lawsuit against Bio..
More news
Sector news : Biopharmaceuticals
02:21pDJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug -- 2nd Updat..
12/06DJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
12/06DJSANOFI : Big Pharma, Short on Blockbusters, Outsources the -2-
12/06DJSANOFI : Big Pharma, Short on Blockbusters, Outsources the Science
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
More sector news : Biopharmaceuticals
News from SeekingAlpha
12/06 Seattle's Aspirations Versus Big Pharma's Appetites
12/02 STOCK EXCHANGE : Model Picks Teach Us To Manage Risk
12/01 AVEXIS : Goldman raises price target to $91
11/29 Alzheimer's Hopefuls Keep Watch For Amyloid Clues
11/28 Biogen Ready To Rally Further
Advertisement
Financials ($)
Sales 2016 11 531 M
EBIT 2016 6 101 M
Net income 2016 4 132 M
Debt 2016 498 M
Yield 2016 -
P/E ratio 2016 15,54
P/E ratio 2017 15,22
EV / Sales 2016 5,54x
EV / Sales 2017 5,26x
Capitalization 63 349 M
More Financials
Chart BIOGEN INC
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 340 $
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
George A. Scangos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
Adriana Karaboutis Executive VP-Technology & Business Solutions
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC-5.27%63 349
CSL LIMITED-6.87%32 792
ALEXION PHARMACEUTICAL..-34.90%27 845
BIOMARIN PHARMACEUTICA..-20.78%14 273
GRIFOLS SA-16.87%11 669
CHONGQING ZHIFEI BIOLO..--.--%4 418
More Results